I am a
Home I AM A Search Login

Papers of the Week

2020 Feb 01




Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.


Bachert C, Zinreich JS, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Amin N, Joish VN, Fan C, Zhang D, Staudinger H, Pirozzi G, Graham NMH, Khan A, Mannent LP
Rhinology. 2020 Feb 01; 58(1):10-17.
PMID: 31671432.


Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus opacification. In a phase 2a study (NCT01920893), dupilumab, a fully human anti-IL-4Rα monoclonal antibody, improved outcomes in CRSwNP refractory to intranasal corticosteroids. We evaluated dupilumab's effect on sinus opacification in relation to effects on nasal polyp burden, symptoms, and health-related quality of life (HRQoL) in patients with CRSwNP.